PMV Pharmaceuticals grabs $30 mln
PMV Pharmaceuticals, which develops p53 targeted small molecule drugs to treat cancer, has raised $30 million in Series A financing. OrbiMed led the round with participation from Osage University Partners and supported by founding investor InterWest Partners. In addition to the funding, Dr. Peter Thompson of OrbiMed has been appointed to PMV's board of directors.
2 December 2014•3 mins read
